BACKGROUND Lancefield Group-B Streptococcus (GBS) emerged as a significant neonatal pathogen with mortality rates of 15 - 50 % in western countries during 1970s. In India, incidence of invasive neonatal GBS diseases is around 0.17 per 1000 live birth and probably is underestimated. Hence, the study was undertaken to evaluate the vaginal GBS colonization in pregnant women along with the neonatal outcome. METHODS The study was single centered, hospital based observational cross-sectional study done in the dept. of Obstetrics & Gynaecology at Agartala Government Medical College (AGMC), and GBP Hospital for one & half years (Jan’ 16 - June’ 17). 250 Pregnant mothers with 31 to 40 weeks of gestation with singleton pregnancy, delivering either by Caesarean section & Vaginal delivery, were included in this study. They were recruited from obstetrics OPD and casualty of AGMC & GBP Hospital. During 1 st pelvic examination, two low vaginal swabs were taken for Gram Staining, and for determination of ß-hemolytic colony in blood agar. After identification of GBS from genitalia, outcome of neonates in these positive cases were evaluated for up to 28 days after delivery. RESULTS GBS was found in 8.8 % of total women recruited and was more common in multi-gravida. GBS vaginal colonization was significantly associated with low birth weight, and preterm delivery (p value 0.01) which is significant. CONCLUSIONS Prevalence of vaginal GBS colonization is more in pregnant mothers, more in multigravidas & is associated with low-birth-weight neonates and preterm delivery. So, there is a need to formulate guidelines for incorporation of detection of vaginal colonization in multi gravidas to determine its prevalence. KEYWORDS Group-B Streptococcus (GBS), Multigravidas, Colonization, Neonates, Pregnant Women
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.